Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Timecourse of NIH-3T3 cells treated with apoptotic inducers (Study ST001740)

Reversed phase NEGATIVE ION MODE (Analysis AN002833)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13	F14	F15	F16	F17	F18	F19	F20	F21	F22	F23	F24	F25	F26	F27	F28	F29	F30	F31	F32	F33	F34	F35	F36	F37	F38	F39	F40	F41	F42	F43	F44	F45
Phosphatidylinositol(16:0/18:1)	ME404219	0.39	0.46	0.34	0.26	0.59	0.74	1.56	0.60	0.49	0.30	0.46	0.43	0.31	0.31	1.25	1.56	0.81	0.55	0.50	0.75	1.28	0.39	0.43	1.11	1.89	4.77	0.79	0.83	1.61	1.66	0.38	0.57	2.06	1.48	3.35	1.60	0.45	0.39	0.73	0.67	0.48	0.73	1.91	3.49	0.42
Phosphatidylinositol(18:0/22:5)	ME404229	0.78	0.86	0.86	0.76	0.75	0.93	0.79	0.80	0.83	0.80	0.80	0.80	0.78	0.76	1.23	0.90	1.01	0.70	0.72	0.87	1.34	0.79	0.81	0.71	1.51	3.79	0.71	0.87	0.98	1.24	0.69	0.77	0.59	1.88	2.86	0.62	0.75	0.82	0.85	0.99	0.78	1.08	1.18	2.16	0.84
Phosphatidylinositol(18:0/22:6)	ME404230	0.72	0.95	0.68	0.62	0.73	0.92	0.90	0.84	0.75	0.80	0.80	0.93	0.70	0.80	1.32	0.98	1.09	0.69	0.58	0.79	1.70	0.71	0.73	0.90	1.35	4.98	0.76	0.62	0.91	1.30	0.39	0.52	0.63	1.40	3.56	0.65	0.55	0.55	0.97	0.94	0.73	0.92	1.16	2.12	0.78
Phosphatidylinositol(16:0/20:3 n-6)	ME404222	0.89	1.04	0.94	0.86	0.78	0.79	0.86	0.78	0.75	0.84	0.74	0.72	0.73	0.54	0.99	1.27	1.00	0.78	0.61	0.86	1.70	0.58	0.71	0.92	1.72	2.72	0.86	0.62	1.57	1.44	0.39	0.49	1.09	1.23	2.75	0.81	0.64	0.73	1.01	0.73	0.80	1.05	1.64	2.28	0.77
Phosphatidylinositol(18:0/20:3 n-6)	ME404224	0.69	0.85	0.78	0.71	0.80	0.87	0.70	0.78	0.82	0.73	0.83	0.80	0.82	0.86	0.94	0.77	0.97	0.78	0.88	0.85	1.44	0.97	0.78	0.84	1.66	2.23	0.90	1.17	1.12	1.56	0.86	0.67	0.76	2.12	2.34	0.91	0.74	0.76	1.04	0.90	0.85	0.93	1.28	1.82	0.86
Phosphatidylinositol(16:1/18:1)	ME404220	0.55	0.52	0.54	0.47	0.86	1.03	1.86	0.63	0.70	0.48	0.61	0.52	0.55	0.57	1.38	1.85	0.60	0.66	0.54	0.99	1.46	0.71	0.47	1.30	1.82	1.71	1.16	0.58	1.30	1.70	0.80	0.72	2.57	0.98	1.01	2.24	0.58	0.54	1.12	0.65	0.52	1.08	1.67	1.47	0.60
Phosphatidylinositol(18:1/18:1)	ME404221	0.62	0.68	0.56	0.56	0.87	1.07	1.64	0.71	0.77	0.60	0.64	0.65	0.50	0.59	1.71	1.79	0.73	0.79	0.48	0.98	1.23	0.47	0.52	1.61	1.77	1.36	1.17	0.65	1.22	1.31	0.47	0.50	2.68	1.22	1.03	2.10	0.55	0.65	0.94	0.60	0.47	1.16	2.02	1.16	0.69
Phosphatidylinositol(18:1/20:3 n-6)	ME404226	1.05	1.02	0.89	0.82	1.20	0.95	1.29	1.00	1.03	0.99	0.84	0.95	0.81	0.95	1.07	1.25	0.84	1.00	0.79	1.11	1.53	0.60	0.57	1.33	1.30	0.89	1.12	0.75	0.95	1.86	0.69	0.52	1.23	1.20	0.89	1.00	0.82	0.83	1.22	0.60	0.62	1.17	1.65	0.61	1.00
Phosphatidylinositol(18:0/20:4)	ME404225	1.12	1.09	1.12	1.12	1.04	1.00	0.78	1.06	1.07	1.17	1.13	1.11	1.15	1.14	0.88	0.74	1.10	1.10	1.32	1.01	0.80	1.27	1.22	0.82	0.71	0.42	0.96	1.25	0.93	0.75	1.31	1.26	0.64	0.82	0.62	0.79	1.17	1.15	0.95	1.18	1.23	0.94	0.69	0.75	1.09
Phosphatidylinositol(16:0/20:4)	ME404223	1.08	1.04	1.03	1.16	1.05	0.96	1.18	1.16	1.10	0.89	1.02	1.12	1.07	1.01	0.84	1.11	1.15	1.09	0.65	1.03	0.83	0.75	1.11	1.01	0.84	0.82	1.05	0.74	1.15	0.85	0.60	1.17	0.96	0.75	0.96	1.01	0.98	1.11	1.06	0.87	1.11	1.05	0.90	1.11	1.12
Phosphatidylinositol(18:1/20:4)	ME404227	1.17	1.13	1.23	1.26	1.17	1.14	1.23	1.21	1.15	1.07	1.08	1.13	1.16	1.11	0.92	1.27	0.88	1.10	0.74	1.16	1.06	0.82	0.93	1.28	0.76	0.33	1.19	0.56	0.83	1.04	0.82	0.84	1.00	0.58	0.46	0.96	1.11	1.09	1.20	0.88	0.90	1.14	0.90	0.36	1.13
Phosphatidylinositol(18:1/20:5)	ME404228	1.15	1.26	1.09	1.25	1.31	1.08	1.50	1.30	1.10	1.12	1.10	1.22	1.19	1.06	1.21	1.45	1.04	1.17	0.44	0.88	1.05	0.68	0.75	1.25	0.81	0.34	1.11	0.50	0.77	1.02	0.88	0.72	1.11	0.58	0.21	1.02	1.07	1.07	1.26	0.86	0.79	1.23	1.15	0.36	1.04

Factors:

F1	hours:0.17 \| treatment:CHX \| concentration:20 µg/ml
F2	hours:0.17 \| treatment:ETO \| concentration:10 µM
F3	hours:0.17 \| treatment:MC \| concentration:10 µM
F4	hours:0.17 \| treatment:Serum \| concentration:-
F5	hours:0.17 \| treatment:STS \| concentration:0.3 µM
F6	hours:0.17 \| treatment:TNFα \| concentration:10 ng/ml
F7	hours:0.17 \| treatment:TPG \| concentration:2 µM
F8	hours:0.17 \| treatment:VAL \| concentration:10 µM
F9	hours:0.17 \| treatment:vehicle (DMSO) \| concentration:-
F10	hours:1 \| treatment:CHX \| concentration:20 µg/ml
F11	hours:1 \| treatment:ETO \| concentration:10 µM
F12	hours:1 \| treatment:MC \| concentration:10 µM
F13	hours:1 \| treatment:Serum \| concentration:-
F14	hours:1 \| treatment:STS \| concentration:0.3 µM
F15	hours:1 \| treatment:TNFα \| concentration:10 ng/ml
F16	hours:1 \| treatment:TPG \| concentration:2 µM
F17	hours:1 \| treatment:VAL \| concentration:10 µM
F18	hours:1 \| treatment:vehicle (DMSO) \| concentration:-
F19	hours:24 \| treatment:CHX \| concentration:20 µg/ml
F20	hours:24 \| treatment:ETO \| concentration:10 µM
F21	hours:24 \| treatment:MC \| concentration:10 µM
F22	hours:24 \| treatment:Serum \| concentration:-
F23	hours:24 \| treatment:STS \| concentration:0.3 µM
F24	hours:24 \| treatment:TNFα \| concentration:10 ng/ml
F25	hours:24 \| treatment:TPG \| concentration:2 µM
F26	hours:24 \| treatment:VAL \| concentration:10 µM
F27	hours:24 \| treatment:vehicle (DMSO) \| concentration:-
F28	hours:48 \| treatment:CHX \| concentration:20 µg/ml
F29	hours:48 \| treatment:ETO \| concentration:10 µM
F30	hours:48 \| treatment:MC \| concentration:10 µM
F31	hours:48 \| treatment:Serum \| concentration:-
F32	hours:48 \| treatment:STS \| concentration:0.3 µM
F33	hours:48 \| treatment:TNFα \| concentration:10 ng/ml
F34	hours:48 \| treatment:TPG \| concentration:2 µM
F35	hours:48 \| treatment:VAL \| concentration:10 µM
F36	hours:48 \| treatment:vehicle (DMSO) \| concentration:-
F37	hours:6 \| treatment:CHX \| concentration:20 µg/ml
F38	hours:6 \| treatment:ETO \| concentration:10 µM
F39	hours:6 \| treatment:MC \| concentration:10 µM
F40	hours:6 \| treatment:Serum \| concentration:-
F41	hours:6 \| treatment:STS \| concentration:0.3 µM
F42	hours:6 \| treatment:TNFα \| concentration:10 ng/ml
F43	hours:6 \| treatment:TPG \| concentration:2 µM
F44	hours:6 \| treatment:VAL \| concentration:10 µM
F45	hours:6 \| treatment:vehicle (DMSO) \| concentration:-

Data matrix